Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) Director Jean Jacques Bienaime acquired 2,000 shares of the stock in a transaction on Friday, August 14th. The stock was bought at an average price of $246.33 per share, with a total value of $492,660.00. Following the transaction, the director directly owned 2,900 shares of the company's stock, valued at approximately $714,357. The trade was a 222.22% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Jean Jacques Bienaime also recently made the following trade(s):
- On Tuesday, May 26th, Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock. The stock was purchased at an average price of $237.80 per share, for a total transaction of $95,120.00.
Ascendis Pharma A/S Stock Up 0.6%
Shares of NASDAQ ASND opened at $248.85 on Wednesday. The firm's fifty day moving average is $251.15 and its 200 day moving average is $237.51. Ascendis Pharma A/S has a 52 week low of $186.05 and a 52 week high of $282.15. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The company has a market cap of $15.52 billion, a price-to-earnings ratio of 19.31 and a beta of 0.39.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The firm had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. On average, equities research analysts expect that Ascendis Pharma A/S will post 4.35 earnings per share for the current year.
Hedge Funds Weigh In On Ascendis Pharma A/S
A number of hedge funds have recently bought and sold shares of ASND. Perceptive Advisors LLC bought a new stake in shares of Ascendis Pharma A/S in the 2nd quarter worth $166,367,000. Wellington Management Group LLP lifted its holdings in shares of Ascendis Pharma A/S by 95.9% during the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company's stock valued at $357,645,000 after purchasing an additional 880,836 shares in the last quarter. Vestal Point Capital LP boosted its position in shares of Ascendis Pharma A/S by 200.0% during the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company's stock valued at $119,286,000 after buying an additional 400,000 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Ascendis Pharma A/S by 29.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company's stock valued at $218,871,000 after buying an additional 232,730 shares during the last quarter. Finally, Fred Alger Management LLC increased its holdings in Ascendis Pharma A/S by 106.3% in the 4th quarter. Fred Alger Management LLC now owns 352,109 shares of the biotechnology company's stock worth $75,084,000 after buying an additional 181,408 shares in the last quarter.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the company. Evercore reiterated an "outperform" rating and issued a $329.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. BMO Capital Markets began coverage on Ascendis Pharma A/S in a report on Tuesday. They set an "outperform" rating and a $319.00 target price for the company. Wells Fargo & Company dropped their price target on Ascendis Pharma A/S from $330.00 to $326.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Ascendis Pharma A/S from a "sell (d)" rating to a "hold (c)" rating in a report on Wednesday, July 15th. Finally, Royal Bank Of Canada boosted their price objective on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an "outperform" rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Buy" and a consensus price target of $300.33.
Check Out Our Latest Analysis on ASND
About Ascendis Pharma A/S
(
Get Free Report)
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
